Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative Immune Response after Vaccination with SOBERANA® 02 and SOBERANA® plus Heterologous Scheme and Natural Infection in Young Children.
Pérez-Nicado R, Massa C, Rodríguez-Noda LM, Müller A, Puga-Gómez R, Ricardo-Delgado Y, Paredes-Moreno B, Rodríguez-González M, García-Ferrer M, Palmero-Álvarez I, Garcés-Hechavarría A, Rivera DG, Valdés-Balbín Y, Vérez-Bencomo V, García-Rivera D, Seliger B. Pérez-Nicado R, et al. Among authors: rodriguez noda lm. Vaccines (Basel). 2023 Oct 25;11(11):1636. doi: 10.3390/vaccines11111636. Vaccines (Basel). 2023. PMID: 38005968 Free PMC article.
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
Eugenia-Toledo-Romaní M, Verdecia-Sánchez L, Rodríguez-González M, Rodríguez-Noda L, Valenzuela-Silva C, Paredes-Moreno B, Sánchez-Ramírez B, Pérez-Nicado R, González-Mugica R, Hernández-García T, Bergado-Baez G, Pi-Estopiñán F, Cruz-Sui O, Fraga-Quintero A, García-Montero M, Palenzuela-Díaz A, Baró-Román G, Mendoza-Hernández I, Fernandez-Castillo S, Climent-Ruiz Y, Santana-Mederos D, Ramírez Gonzalez U, García-Vega Y, Pérez-Massón B, Guang-Wu-Chen, Boggiano-Ayo T, Ojito-Magaz E, Rivera DG, Valdés-Balbín Y, García-Rivera D, Vérez-Bencomo V; SOBERANA Research Group; Gómez-Maceo Y, Reyes-Matienzo R, Manuel Coviella-Artime J, Morffi-Cinta I, Martínez-Pérez M, Castillo-Quintana I, Garcés-Hechavarría A, Valera-Fernández R, Martínez-Bedoya D, Garrido-Arteaga R, Cardoso-SanJorge F, Quintero Moreno L, Ontivero-Pino I, Teresa Pérez-Guevara M, Morales-García M, Noa-Romero E, Orosa-Vázquez I, Díaz-Hernández M, Rojas G, Tundidor Y, García-López E, Muñoz-Morejon Y, Galano-Frutos E, Rodríguez-Alvarez J, Arteaga A, Medina Nápoles M, Espi Ávila J, Fontanies Fernández M. Eugenia-Toledo-Romaní M, et al. Vaccine. 2022 Jul 29;40(31):4220-4230. doi: 10.1016/j.vaccine.2022.05.082. Epub 2022 Jun 6. Vaccine. 2022. PMID: 35691871 Free PMC article. Clinical Trial.
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults.
Toledo-Romani ME, García-Carmenate M, Verdecia-Sánchez L, Pérez-Rodríguez S, Rodriguez-González M, Valenzuela-Silva C, Paredes-Moreno B, Sanchez-Ramirez B, González-Mugica R, Hernández-Garcia T, Orosa-Vázquez I, Díaz-Hernández M, Pérez-Guevara MT, Enriquez-Puertas J, Noa-Romero E, Palenzuela-Diaz A, Baro-Roman G, Mendoza-Hernández I, Muñoz Y, Gómez-Maceo Y, Santos-Vega BL, Fernandez-Castillo S, Climent-Ruiz Y, Rodríguez-Noda L, Santana-Mederos D, García-Vega Y, Chen GW, Doroud D, Biglari A, Boggiano-Ayo T, Valdés-Balbín Y, Rivera DG, García-Rivera D, Vérez-Bencomo V; SOBERANA Research Group. Toledo-Romani ME, et al. Med. 2022 Nov 11;3(11):760-773.e5. doi: 10.1016/j.medj.2022.08.001. Epub 2022 Aug 8. Med. 2022. PMID: 35998623 Free PMC article. Clinical Trial.
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children.
Puga-Gómez R, Ricardo-Delgado Y, Rojas-Iriarte C, Céspedes-Henriquez L, Piedra-Bello M, Vega-Mendoza D, Pérez NP, Paredes-Moreno B, Rodríguez-González M, Valenzuela-Silva C, Sánchez-Ramírez B, Rodríguez-Noda L, Pérez-Nicado R, González-Mugica R, Hernández-García T, Fundora-Barrios T, Echevarría MD, Enriquez-Puertas JM, Infante-Hernández Y, Palenzuela-Díaz A, Gato-Orozco E, Chappi-Estévez Y, Francisco-Pérez JC, Suarez-Martinez M, Castillo-Quintana IC, Fernandez-Castillo S, Climent-Ruiz Y, Santana-Mederos D, García-Vega Y, Toledo-Romani ME, Doroud D, Biglari A, Valdés-Balbín Y, García-Rivera D, Vérez-Bencomo V; SOBERANA Research Group. Puga-Gómez R, et al. Int J Infect Dis. 2023 Jan;126:164-173. doi: 10.1016/j.ijid.2022.11.016. Epub 2022 Nov 18. Int J Infect Dis. 2023. PMID: 36403819 Free PMC article. Clinical Trial.
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial.
Chang-Monteagudo A, Ochoa-Azze R, Climent-Ruiz Y, Macías-Abraham C, Rodríguez-Noda L, Valenzuela-Silva C, Sánchez-Ramírez B, Perez-Nicado R, Hernández-García T, Orosa-Vázquez I, Díaz-Hernández M, García-García MLÁ, Jerez-Barceló Y, Triana-Marrero Y, Ruiz-Villegas L, Rodríguez-Prieto LD, Puga-Gómez R, Guerra-Chaviano PP, Zúñiga-Rosales Y, Marcheco-Teruel B, Rodríguez-Acosta M, Noa-Romero E, Enríquez-Puertas J, Porto-González D, Fernández-Medina O, Valdés-Zayas A, Chen GW, Herrera-Martínez L, Valdés-Balbín Y, García-Rivera D, Verez-Bencomo V. Chang-Monteagudo A, et al. Lancet Reg Health Am. 2021 Dec;4:100079. doi: 10.1016/j.lana.2021.100079. Epub 2021 Sep 15. Lancet Reg Health Am. 2021. PMID: 34541571 Free PMC article.
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
Pérez-Rodríguez S, de la Caridad Rodríguez-González M, Ochoa-Azze R, Climent-Ruiz Y, Alberto González-Delgado C, Paredes-Moreno B, Valenzuela-Silva C, Rodríguez-Noda L, Perez-Nicado R, González-Mugica R, Martínez-Pérez M, Sánchez-Ramírez B, Hernández-García T, Díaz-Machado A, Tamayo-Rodríguez M, Martín-Trujillo A, Rubino-Moreno J, Suárez-Batista A, Dubed-Echevarría M, Teresa Pérez-Guevara M, Amoroto-Roig M, Chappi-Estévez Y, Bergado-Báez G, Pi-Estopiñán F, Chen GW, Valdés-Balbín Y, García-Rivera D, Verez-Bencomo V. Pérez-Rodríguez S, et al. Vaccine. 2022 Mar 18;40(13):2068-2075. doi: 10.1016/j.vaccine.2022.02.029. Epub 2022 Feb 8. Vaccine. 2022. PMID: 35164986 Free PMC article. Clinical Trial.
Prevalence of Pneumococcal Nasopharyngeal Carriage Among Children 2-18 Months of Age: Baseline Study Pre Introduction of Pneumococcal Vaccination in Cuba.
Toledo ME, Casanova MF, Linares-Pérez N, García-Rivera D, Toraño Peraza G, Barcos Pina I, Montes de Oca M, Rodriguez-Noda LM, Mirabal M, Paredes B, Chávez Amaro DM, Santana Mederos D, Valdés-Balbín Y, Verez-Bencomo V; Finlay Vaccine Institute Laboratory-Pneumococci Group and Cienfuegos Local Research Team Pneumococci Project. Toledo ME, et al. Among authors: rodriguez noda lm. Pediatr Infect Dis J. 2017 Jan;36(1):e22-e28. doi: 10.1097/INF.0000000000001341. Pediatr Infect Dis J. 2017. PMID: 27649366
Influence of the Co-Administration of Heptavalent Conjugate Vaccine PCV7-TT on the Immunological Response Elicited by VA-MENGOC-BC® and Heberpenta®-L in Rabbits.
Espinosa-Viñals C, García-Rivera D, Rodríguez Noda L, Amador Gómez A, Nicot M, Valle O, Núñez JF, Martin Y, Santana D, Valdés Y, Vérez Bencomo V. Espinosa-Viñals C, et al. Immunol Invest. 2017 May;46(4):395-408. doi: 10.1080/08820139.2017.1288238. Epub 2017 Apr 5. Immunol Invest. 2017. PMID: 28379053
Safety and immunogenicity of the Cuban heptavalent pneumococcal conjugate vaccine in healthy infants. Results from a double-blind randomized control trial Phase I.
Martínez CPD, Linares-Pérez N, Toledo-Romaní ME, Delgado YR, Gómez RP, Moreno BP, Rodriguez-Noda LM, Sosa MM, Mederos DS, García-Rivera D, Valdés-Balbín Y, Goldblatt D, Vérez-Bencomo V; Havana-Pneumococci Clinical Group; Finlay-Pneumococci Project. Martínez CPD, et al. Among authors: rodriguez noda lm. Vaccine. 2018 Aug 6;36(32 Pt B):4944-4951. doi: 10.1016/j.vaccine.2018.05.027. Epub 2018 Jul 10. Vaccine. 2018. PMID: 30005948 Clinical Trial.
15 results